OnKure Therapeutics, Inc.
NASDAQ:OKURBiotechnology
Healthcare
$2.76 +0.23%
+$0.01 today
- Market cap
- $111.79M
- Beta
- 0.28
- P/E (TTM)
- -1.0
- EPS (TTM)
- -$4.30
52W Low $1.91High $5.38
Volume 0.14M
Average 0.37M
Income Statement
Follow revenue through to earnings.
Revenue
$0.00
FY 2025 · Annual
Operating Income
-$62.95M
FY 2025 · Annual
Net Income
-$59.52M
FY 2025 · Annual
Income Statement
USD
Metric | FY 2021 Dec 2021 | FY 2022 Dec 2022 | FY 2023 Dec 2023 | FY 2024 Dec 2024 | FY 2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 50K | 0 | 0 | 0 | 830K |
| Gross Profit | (50K) | 0 | 0 | 0 | (830K) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 28.12M | 25.86M | 32.12M | 43.8M | 48.26M |
| Selling, General & Admin | 11.65M | 3.9M | 4.82M | 10.59M | 14.69M |
| Operating Expenses | 39.77M | 29.77M | 36.93M | 54.39M | 62.12M |
| Depreciation & Amortization | 50K | 387K | 560K | 662K | 830K |
| EBITDA | (39.72M) | (29.13M) | (34.75M) | (51.71M) | (58.69M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (39.82M) | (29.77M) | (36.93M) | (54.39M) | (62.95M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 254K | 1.62M | 2.01M | 3.44M |
| Interest Expense | 0 | 0 | 0 | 300K | 0 |
| Other Income / Expenses | 48K | 254K | 1.62M | 1.71M | 3.43M |
| Income Before Tax | (39.77M) | (29.51M) | (35.31M) | (52.67M) | (59.52M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (39.77M) | (29.51M) | (35.31M) | (52.67M) | (59.52M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (21.92) | (2.21) | (2.65) | (3.95) | (4.40) |
| EPS (Diluted) | (21.92) | (2.21) | (2.65) | (3.95) | (4.40) |
| 1.81M | 13.34M | 13.34M | 13.34M | 13.52M | |
| 1.81M | 13.34M | 13.34M | 13.34M | 13.52M |
OKUR Earnings Waterfall · TTM
NASDAQ:OKUR · Revenue to Net Income
Key Ratios
EPS$-4.33
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-0.7
P/S Ratio0.0
Analysis
$0 of revenue converted into -$58.7M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-4.33, tying the income statement back to per-share earnings.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Nov 4, 2026 | |
| 10-Q | Quarterly report | Nov 4, 2026 | |
| SC 13G | SC 13G filing | Oct 7, 2026 | |
| 4 | Statement of changes in beneficial ownership | Sep 23, 2026 | |
| 4 | Statement of changes in beneficial ownership | Sep 23, 2026 |
How much revenue does OKUR generate?
OnKure Therapeutics, Inc. (OKUR) reported $0.00 of revenue in fiscal 2025.
Is OKUR profitable?
OnKure Therapeutics, Inc. (OKUR) reported -$59.52M of net income.
Continue the stock analysis
Jump to another research area for this company.